Clinical trial

Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis

NCT05540938

Study summary

ClinicalTrials.gov

Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Wangbi granules Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Wangbi granules simulant Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-05-23

PhasePHASE4

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

Wangbi granulesDRUG

Wangbi granules simulantDRUG

Sponsors & collaborators

China-Japan Friendship Hospitallead sponsor

Peking Union Medical College Hospitalcollaborator

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicinecollaborator

The 980th Hospital of PLA Joint Logistics Support Forcecollaborator

The Second Affiliated Hospital of Zhejiang Chinese Medical Universitycollaborator

Southwest Hospital, Chinacollaborator

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05540938 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.